The effect of matrix metalloproteinase-3 deficiency on pulmonary surfactant in a mouse model of acute lung injury

Yamashita, Cory; Cybulskie, Candice; Milos, Scott; Zuo, Yi Y.; McCaig, Lynda; Veldhuizen, Ruud A. W.

doi:10.1139/cjpp-2015-0377

Cited by 6 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies conducted on animal models have found that the lungs of MMP3 gene‐deficient mice can be protected by inflammatory stimulation 5,11,12 . However, a study by Yamashita 13 indicated that MMP3 deficiency helps maintain the function of pulmonary surfactant to some extent and thereby protects the lungs from injury caused by physiological changes. This suggests that MMP3 plays a regulatory role in lung injury and repair.…”

Section: Discussionmentioning

confidence: 99%

Matrix metalloproteinase 3 as a valuable marker for patients with COVID‐19

Shi

Shu

Shen

et al. 2020

Journal of Medical Virology

View full text Add to dashboard Cite

The situation of the coronavirus disease 2019 (COVID‐19) continues to evolve, our study explored the significance of serum levels of matrix metalloproteinase 3 (MMP3) as a marker for patients with COVID‐19. Sixty‐two COVID‐19 patients in the First Hospital of Hunan University of Chinese Medicine and Loudi Center for Diseases Prevention and Control, from January to March 2020, were sampled as the novel coronavirus pneumonia infected group. One hundred and thirty‐one cases from the First Hospital of Hunan University of Chinese Medicine, including 67 healthy individuals and 64 non‐COVID‐19 inpatients, served as the noninfected group. Approximately every 5 days, sera from 20 cases were collected and analyzed three times, using an automatic biochemical analyzer, to detect serum MMP3 concentrations. Correlation was analyzed between MMP3 and other proinflammatory cytokines. Following normality tests, differences in serum MMP3 levels between the infected and noninfected group were analyzed via SPSS (version 25.0) software, using the Wilcoxon rank sum test. The MMP3 concentration was 44.44 (23.46 ~ 72.12) ng/mL in the infected group and 32.42 (28.16 ~ 41.21) ng/mL in the noninfected group. The difference between the two groups was statistically significant ( Z = −2.799, P = .005 < .05). A positive correlation was found between MMP3 and interleukin 1β (IL‐1β; r = .681, P = .000 < .05), and IL‐6 ( r = .529, P = .002 < .05). Serum MMP3 concentration, measured over three separate time points, were 55.98 (30.80 ~ 75.97) ng/mL, 34.84 (0.00 ~ 51.84) ng/mL, and 5.71 (0.00 ~ 40.46) ng/mL, respectively. Detection of serum MMP3 levels may play an important role in the development of therapeutic approaches for COVID‐19 and may indicate the severity of disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Matrix metalloproteinase 3 as a valuable marker for patients with COVID‐19

Shi

Shu

Shen

et al. 2020

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Studies have revealed the critical involvement of MMPs (especially MMP-3) in the pathogenesis of lung-associated disorders, such as pulmonary fibrosis and ARDS. Additionally, MMP-3 deficiency was associated with normal function of lung surfactant, which in turn was related to lung protection during pathological settings [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

Association of the matrix metalloproteinases (MMPs) family gene polymorphisms and the risk of coronavirus disease 2019 (COVID-19); implications of contribution for development of neurological symptoms in the COVID-19 patients

et al. 2022

View full text Add to dashboard Cite

Background Seemingly, the Matrix metalloproteinases (MMPs) play a role in the etiopathogenesis of coronavirus disease 2019 (COVID-19). Here in this study, we determined the association of MMP9 rs3918242, MMP3 rs3025058, and MMP2 rs243865 polymorphisms with the risk of COVID-19, especially in those with neurological syndrome (NS). Methods We enrolled 500 patients with COVID-19 and 500 healthy individuals. To genotype the target SNPs, the Real-time allelic discrimination technique was used. To determine serum levels of MMPs, Enzyme-linked immunosorbent assay (ELISA) was exerted. Results The MMP9 gene rs3918242 and MMP3 gene rs3025058 SNP were significantly associated with increased COVID-19 risk and susceptibility to COVID-19 with NS. The serum level of MMP-9 and MMP-3 was significantly higher in COVID-19 cases compared with the healthy controls. Serum MMP-9 and MMP-3 levels were also higher in COVID-19 subjects with NS in comparison to the healthy controls. The polymorphisms in MMP genes were not associated with serum level of MMPs. Conclusion MMP9 and MMP3 gene polymorphisms increases the susceptibility to COVID-19 as well as COVID-19 with neurologic syndrome, but they probably have no role in the regulation of serum MMP-9 and MMP-3 levels.

show abstract

“…Studies conducted on animal models have found that the lungs of MMP3 gene deficient mice can be protected by inflammatory stimulation. [4,10,11] However, a study by Yamashita [12] (2016) indicated that MMP3 deficiency helps maintain the function of pulmonary surfactant to some extent and thereby protects the lungs from injury caused by physiological changes. This suggests that MMP3 plays a regulatory role in lung injury and repair.…”

Section: Discussionmentioning

confidence: 99%